NEW YORK (GenomeWeb News) – The Translational Genomics Research Institute has struck a collaborative research agreement with Ventana Medical Systems to study new biomarkers for use in treating pancreatic cancer, Ventana said today.

TGen and Roche Group member Ventana plan to discover and develop diagnostic, prognostic, and drug biomarkers that can be used to detect the disease early in its course, and to develop better, personalized treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.